eXoZymes (EXOZ) Competitors $14.50 -0.98 (-6.33%) As of 09/29/2025 02:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EXOZ vs. SLDB, CRVS, CMPX, RGNX, OCGN, CYRX, MNPR, ITOS, FULC, and ALMSShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Solid Biosciences (SLDB), Corvus Pharmaceuticals (CRVS), Compass Therapeutics (CMPX), REGENXBIO (RGNX), Ocugen (OCGN), CryoPort (CYRX), Monopar Therapeutics (MNPR), iTeos Therapeutics (ITOS), Fulcrum Therapeutics (FULC), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Solid Biosciences Corvus Pharmaceuticals Compass Therapeutics REGENXBIO Ocugen CryoPort Monopar Therapeutics iTeos Therapeutics Fulcrum Therapeutics Alumis eXoZymes (NASDAQ:EXOZ) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Does the media refer more to EXOZ or SLDB? In the previous week, Solid Biosciences had 6 more articles in the media than eXoZymes. MarketBeat recorded 7 mentions for Solid Biosciences and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.89 beat Solid Biosciences' score of 1.06 indicating that eXoZymes is being referred to more favorably in the media. Company Overall Sentiment eXoZymes Very Positive Solid Biosciences Positive Which has better earnings & valuation, EXOZ or SLDB? eXoZymes has higher earnings, but lower revenue than Solid Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymes$70K1,737.93-$5.86MN/AN/ASolid Biosciences$8.09M57.46-$124.70M-$2.80-2.13 Do analysts rate EXOZ or SLDB? Solid Biosciences has a consensus target price of $15.00, suggesting a potential upside of 151.26%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Do institutionals & insiders hold more shares of EXOZ or SLDB? 81.5% of Solid Biosciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 13.6% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is EXOZ or SLDB more profitable? Solid Biosciences' return on equity of -69.70% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Solid Biosciences N/A -69.70%-56.74% SummarySolid Biosciences beats eXoZymes on 9 of the 13 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.84M$3.11B$5.68B$10.37BDividend YieldN/A2.43%5.78%4.70%P/E RatioN/A21.6975.6026.39Price / Sales1,737.93405.52502.81220.60Price / CashN/A43.2725.6730.68Price / Book11.609.7212.826.40Net Income-$5.86M-$52.86M$3.29B$276.69M7 Day Performance-0.68%2.40%1.39%0.12%1 Month Performance49.48%8.67%4.62%6.78%1 Year PerformanceN/A19.51%66.62%26.72% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymes1.114 of 5 stars$14.50-6.3%N/AN/A$129.84M$70K0.0029Positive NewsGap UpSLDBSolid Biosciences3.0616 of 5 stars$5.92-5.1%$15.00+153.4%-15.4%$485.90M$8.09M-2.11100CRVSCorvus Pharmaceuticals1.9 of 5 stars$6.61+2.0%$13.00+96.7%+41.4%$482.85MN/A-6.5430Positive NewsCMPXCompass Therapeutics2.6993 of 5 stars$3.49flat$13.88+297.6%+103.2%$482.61M$850K-7.7620RGNXREGENXBIO4.5427 of 5 stars$9.36-1.9%$28.38+203.2%-8.8%$481.91M$83.33M-2.72370OCGNOcugen1.3721 of 5 stars$1.52-7.3%$6.00+294.7%+42.2%$479.38M$4.05M-7.6080High Trading VolumeCYRXCryoPort3.7962 of 5 stars$9.44-1.3%$12.56+33.0%+17.6%$478.64M$228.38M7.101,186MNPRMonopar Therapeutics2.5726 of 5 stars$77.44+6.0%$82.33+6.3%+1,021.1%$450.65MN/A-23.2610Analyst ForecastAnalyst RevisionGap UpITOSiTeos Therapeutics3.2614 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790FULCFulcrum Therapeutics1.4198 of 5 stars$8.50+3.0%$9.60+12.9%+130.0%$446.26M$80M-6.97100Positive NewsHigh Trading VolumeALMSAlumis3.3667 of 5 stars$3.99-3.6%$20.17+405.4%-64.6%$430.83MN/A0.00N/A Related Companies and Tools Related Companies Solid Biosciences Competitors Corvus Pharmaceuticals Competitors Compass Therapeutics Competitors REGENXBIO Competitors Ocugen Competitors CryoPort Competitors Monopar Therapeutics Competitors iTeos Therapeutics Competitors Fulcrum Therapeutics Competitors Alumis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 9/30/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDefense Billions Flow Into Critical Minerals — Here’s Why Gold’s KeyWhat do missile defense systems and gold miners have in common? More than most investors realize. The Unite...The Tomorrow Investor | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXOZ Stock Alerts